Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.

Merck Vaccine Network – Africa (MVN-A)

Advancing the Dialogue Toward a Healthier Future

Overview Approach Performance Priorities and Goals

In sub-Saharan Africa, more than 9.6 million children each year do not receive the most basic vaccines. One of the major reasons for low vaccination rates in developing nations, according to the World Health Organization (WHO), is the lack of adequate numbers of skilled health care professionals. In 2003, the GAVI Alliance (GAVI) endorsed the planned activities of the Merck Vaccine Network – Africa (MVN-A), our philanthropic initiative to develop training centers in Africa to help increase the capacity of immunization programs to effectively deliver vaccines.



























The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.

*Software to view files presented in PDF or SWF format is available at no charge through the Adobe Web site. Get Adobe Reader Get Adobe Flash Player

Copyright © 2009 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.  Privacy  Terms of Use  Sitemap